Literature DB >> 16401646

Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus.

Shona L Kirk1, Marie Cahir, Gavin P Reynolds.   

Abstract

Many atypical antipsychotic drugs, such as clozapine, can induce significant weight gain which can have serious implications for drug compliance and morbidity. Food intake and weight gain are regulated primarily by the hypothalamus; the arcuate nucleus (ARC) of the hypothalamus is the region initially mediating the effects of circulating hormones on food intake. Neuropeptide Y (NPY) is an important hypothalamic peptide involved in body weight regulation. Immunohistochemical staining of NPY in the ARC was carried out in male Sprague-Dawley rats treated with haloperidol (1.5 mg/kg, i.p.) or clozapine (25 mg/kg, i.p.) for 3 weeks. Clozapine, but not haloperidol, produced an increase in NPY immunoreactivity in the ARC, suggesting that effects on NPY may be involved in increases in body weight following clozapine treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16401646     DOI: 10.1177/0269881106061199

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  11 in total

Review 1.  Atypical antipsychotic-induced weight gain: insights into mechanisms of action.

Authors:  James L Roerig; Kristine J Steffen; James E Mitchell
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.

Authors:  Nima Davoodi; Mikhail Kalinichev; Sergei A Korneev; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2008-12-04       Impact factor: 4.530

Review 3.  Pharmacological management of atypical antipsychotic-induced weight gain.

Authors:  Trino Baptista; Yamily ElFakih; Euderruh Uzcátegui; Ignacio Sandia; Eduardo Tálamo; Enma Araujo de Baptista; Serge Beaulieu
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation.

Authors:  Johan Fernø; Luis Varela; Silje Skrede; María Jesús Vázquez; Rubén Nogueiras; Carlos Diéguez; Antonio Vidal-Puig; Vidar M Steen; Miguel López
Journal:  PLoS One       Date:  2011-06-13       Impact factor: 3.240

5.  Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.

Authors:  Katrina Weston-Green; Xu-Feng Huang; Chao Deng
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

Review 6.  Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders.

Authors:  Ileana Cristina Miron; Victoriţa Cătălina Baroană; Florica Popescu; Floriana Ionică
Journal:  Curr Health Sci J       Date:  2013-12-29

7.  A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia.

Authors:  Anabel Perez-Gomez; Maria Carretero; Natalie Weber; Veronika Peterka; Alan To; Viktoriya Titova; Gregory Solis; Olivia Osborn; Michael Petrascheck
Journal:  Nat Commun       Date:  2018-12-10       Impact factor: 14.919

8.  Sex-dependent alterations of dopamine receptor and glucose transporter density in rat hypothalamus under long-term clozapine and haloperidol medication.

Authors:  Marie-Luise Bouvier; Karin Fehsel; Andrea Schmitt; Eva Meisenzahl-Lechner; Wolfgang Gaebel; Martina von Wilmsdorff
Journal:  Brain Behav       Date:  2020-06-11       Impact factor: 2.708

Review 9.  A Focused Review of the Metabolic Side-Effects of Clozapine.

Authors:  Jessica W Y Yuen; David D Kim; Ric M Procyshyn; William J Panenka; William G Honer; Alasdair M Barr
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-25       Impact factor: 5.555

10.  Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies.

Authors:  Fabio Panariello; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Schizophr Res Treatment       Date:  2010-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.